Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s ...

Medically reviewed by Marla Anderson, MDMedically reviewed by Marla Anderson, MD Non-small cell ... (CXR) to look for a tumor (masses) in the lungs. A chest X-ray is a painless test that can ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Lung cancer starts in your lungs and can spread to other parts of your body. There are more than 20 kinds of lung cancer. Some other conditions can have similar warning signs to lung cancer. It ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...